Drug Profile
Gadoversetamide
Alternative Names: Gd-DTPA-BMEA; MP 1177; OptiMARKLatest Information Update: 19 Aug 2017
Price :
$50
*
At a glance
- Originator Mallinckrodt Medical
- Class Contrast media; Organometallic compounds; Small molecules
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed CNS disorders; Liver disorders
- No development reported Myocardial infarction
Most Recent Events
- 20 Jul 2017 Mallinckrodt withdraws the phase III SHERLOC trial in Kidney disorders prior to enrolment because of unavailability of the study drug in USA (IV) (NCT00811863)
- 10 Jul 2017 Guerbet announces intention to withdraw sales of gadoversetamide in the European Union starting 26 July 2017 and to phase out in other geographies by 2019
- 10 Mar 2017 EMA's Pharmacovigilance Risk Assessment Committee recommends suspension of gadoversetamide from the market in the European Union